EUVIMEDEUVIMED entdecken
Crossref

Anti–MUC1 nanobody can synergize the Tamoxifen and Herceptin effects on breast cancer cells by inducing ER, PR and HER2 overexpression

Mahdieh Shokrollahi Barough, Neda Jalili, Soodabe Shafiee, Malihe Salehi, Nazanin Naseri, Mohammad Amin Javidi, Aysooda Hosseinzadeh, Leila Farahmand

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110792 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Mahdieh Shokrollahi Barough und 7 weiteren Autor:innen. Beteiligte Einrichtung: ATMP Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran 1517964311, Iran; Recombinant Proteins Department, Breast Can…. Hauptthemen laut MEDLINE: Tamoxifen, Breast Neoplasms, Mucin-1, Trastuzumab. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: ACECR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: One of the most pressing concerns associated with breast cancer-targeted therapies is resistance to Tamoxifen and Herceptin. Such drug resistance is usually characterized by reduced expression of certain cell surface receptors. Some biological regimens can induce perceptible overexpression of these receptors in favor of drug responsiveness. MATERIAL AND METHODS: In this research, drug-responsive MCF-7 and SKBR-3, along with drug-resistant MCF-7R (Tamoxifen resistant) and JIMT-1 (Herceptin resistant) breast cancer cell lines in 2D and 3D cultures were exposed to anti-MUC1 nanobody and then assessed for their ER, PR, and HER2 gene and protein expression using qRT-PCR and immunofluorescent staining analyses. Cell viability and the synergistic relationships of combination treatments were determined with MTT assay followed by CompuSyn software. Apoptotic cells were evaluated with Annexin V/propidium Iodide (PI) and acridine orange/ethidium bromide (AO/EB) staining. RESULTS: Anti-MUC1 exposure elevated the expression levels of ER (42 folds), PR (18.5 folds), and HER2 (4.7 folds). As a result of co-treatment, the IC50 levels for Tamoxifen and Herceptin were reduced by up to 10 and 3 folds, respectively. MCF-7R cells responded positively to Tamoxifen, as evidenced by a 5-fold reduction in the IC50 and enhanced apoptosis. CONCLUSION: The ER, PR, and HER2 overexpression after MUC1 blocking could signal drug hypersensitization and facilitate drug resistance management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TamoxifenBreast NeoplasmsMucin-1TrastuzumabSingle-Domain AntibodiesHumansErb-b2 Receptor Tyrosine KinasesFemaleReceptors, EstrogenCell Line, TumorApoptosisReceptors, ProgesteroneDrug SynergismDrug Resistance, NeoplasmMCF-7 CellsCell SurvivalGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

3D spheroidApoptosisDrug resistanceImmunofluorescence stainingSynergistic effect

Substanzen

TamoxifenErb-b2 Receptor Tyrosine KinasesMucin-1TrastuzumabERBB2 protein, humanReceptors, EstrogenSingle-Domain AntibodiesMUC1 protein, humanReceptors, Progesterone

Autor:innen und Institutionen

  • ATMP Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran 1517964311, Iran; Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran; De…
  • Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
  • Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran. Electronic address: laylafarahmand@gmail.com.

Förderung

  • ACECR

Zitieren

APA

Shokrollahi Barough, M., Jalili, N., Shafiee, S., Salehi, M., Naseri, N., Javidi, M. A., Hosseinzadeh, A., & Farahmand, L. (2023). Anti–MUC1 nanobody can synergize the Tamoxifen and Herceptin effects on breast cancer cells by inducing ER, PR and HER2 overexpression. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110792

Vancouver

Shokrollahi Barough M, Jalili N, Shafiee S, Salehi M, Naseri N, Javidi MA, et al. Anti–MUC1 nanobody can synergize the Tamoxifen and Herceptin effects on breast cancer cells by inducing ER, PR and HER2 overexpression. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110792

BibTeX
@article{ShokrollahiBarough2023,
  author = {Shokrollahi Barough, Mahdieh and Jalili, Neda and Shafiee, Soodabe and Salehi, Malihe and Naseri, Nazanin and Javidi, Mohammad Amin and Hosseinzadeh, Aysooda and Farahmand, Leila},
  title = {Anti–MUC1 nanobody can synergize the Tamoxifen and Herceptin effects on breast cancer cells by inducing ER, PR and HER2 overexpression},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110792}
}
Kostenlos starten →